Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)560.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change-52.34%
  • Beta1.3953
Data delayed at least 20 minutes, as of Feb 06 2026 08:08 GMT.
More ▼

Profile data is unavailable for this security.

About the company

4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.

  • Revenue in GBP (TTM)1.78m
  • Net income in GBP-14.41m
  • Incorporated2020
  • Employees--
  • Location
    4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
  • Phone+44 12 2396 7943
  • Websitehttps://www.4basebio.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m32.07m10.0032.07m10.00
ImmuPharma PLC0.00-3.93m32.07m6.0032.07m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Skinbiotherapeutics PLC4.64m-696.25k52.43m41.0052.43m41.00
Hemogenyx Pharmaceuticals PLC0.00-7.81m66.45m16.0066.45m16.00
4Basebio PLC1.78m-14.41m87.02m--87.02m--
Bioventix PLC13.12m7.58m88.82m16.0088.82m16.00
Scancell Holdings Plc4.71m-5.51m134.91m60.00134.91m60.00
Faron Pharmaceuticals Oy0.00-26.87m193.41m25.00193.41m25.00
Data as of Feb 06 2026. Currency figures normalised to 4Basebio PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.40%Per cent of shares held by top holders
HolderShares% Held
M&G Investment Management Ltd.as of 30 Sep 20251.96m12.62%
Hargreaves Lansdown Fund Managers Ltd.as of 02 Jan 2026161.00k1.04%
Aramea Asset Management AGas of 30 Jun 2022143.33k0.92%
Bankinter Gesti�n de Activos SA SGIICas of 02 Jan 2026123.00k0.79%
KW Investment Management Ltd.as of 02 Jan 202664.00k0.41%
HSBC Bank Plc (Market-Maker)as of 02 Jan 202632.00k0.21%
Rathbones Investment Management Ltd.as of 02 Jan 202630.00k0.19%
DWS Investment GmbHas of 31 Oct 202513.36k0.09%
Renta 4 Sociedad de Valores SAas of 02 Jan 202613.00k0.08%
Winterflood Securities Ltd (Market-Maker)as of 02 Jan 20268.00k0.05%
More ▼
Data from 31 Mar 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.